stoxline Quote Chart Rank Option Currency Glossary
  
Theravance Biopharma, Inc. (TBPH)
8.64  -0.18 (-2.04%)    06-12 16:00
Open: 9.01
High: 9.01
Volume: 217,488
  
Pre. Close: 8.82
Low: 8.6
Market Cap: 420(M)
Technical analysis
2024-06-12 4:25:23 PM
Short term     
Mid term     
Targets 6-month :  10.83 1-year :  11.66
Resists First :  9.27 Second :  9.98
Pivot price 8.64
Supports First :  8.13 Second :  6.76
MAs MA(5) :  8.76 MA(20) :  8.82
MA(100) :  9.06 MA(250) :  9.58
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  44.3 D(3) :  43.9
RSI RSI(14): 44.3
52-week High :  11.71 Low :  8.13
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TBPH ] has closed above bottom band by 49.8%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.04 - 9.09 9.09 - 9.13
Low: 8.45 - 8.52 8.52 - 8.57
Close: 8.54 - 8.64 8.64 - 8.72
Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Headline News

Tue, 11 Jun 2024
When Can We Expect A Profit From Theravance Biopharma Inc (NASDAQ:TBPH)? - Yahoo Sport Australia

Fri, 07 Jun 2024
Theravance Biopharma to Host Investor and Analyst Day on December 12th - Yahoo Singapore News

Tue, 21 May 2024
Theravance Biopharma First Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Mon, 13 May 2024
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript - Seeking Alpha

Mon, 13 May 2024
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Thu, 09 May 2024
Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 49 (M)
Shares Float 15 (M)
Held by Insiders 14.5 (%)
Held by Institutions 104.4 (%)
Shares Short 5,890 (K)
Shares Short P.Month 6,430 (K)
Stock Financials
EPS -0.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.21
Profit Margin -72.8 %
Operating Margin -77.3 %
Return on Assets (ttm) -5.7 %
Return on Equity (ttm) -15.6 %
Qtrly Rev. Growth 39.2 %
Gross Profit (p.s.) 0
Sales Per Share 1.26
EBITDA (p.s.) -0.86
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -9.71
PEG Ratio -0.3
Price to Book value 2.04
Price to Sales 6.83
Price to Cash Flow -25.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android